Bellus Health Inc

BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BELLUS Health is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys. The lead program KIACTA™, a novel drug candidate, is in data review after announcing on June 20, 2016 top-line results from its Phase 3 study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. BELLUS Health is partnered with global private equity firm Auven Therapeutics for the development of KIACTA™. KIACTA™ is also being developed as a treatment in a second indication called sarcoidosis, a rare, potentially fatal inflammatory condition that affects the lungs. An investigational new drug application (IND) for a Phase 2/3 clinical study is expected to be filed with the U.S. Food and Drug Administration in 2016. In addition, BELLUS Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS). sHUS often leads to dialysis, chronic kidney disease and in some cases death, particularly in children. Shigamab™ pre-clinical studies for the treatment of sHUS are currently underway.  BELLUS Health’s pipeline also includes a research-stage project for the treatment of AL amyloidosis, a rare disease in which amyloid protein builds up and causes dysfunction in various parts of the body.

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference. Presentation Details: Event: Jefferies Virtual Lon

BELLUS Health to Participate in Jefferies Virtual London Healthcare Conference

Bellus (BLU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Bellus Health (BLU) Q3 Earnings Expected to Decline

After establishing a holding in Bellus Health Inc. (NASDAQ:BLU) during the second quarter, billionaire investor Steven Cohen (Trades, Portfolio) disclosed earlier this week his firm, Point72 Asset Management, upped the position by 1,712.12%.

Steven Cohen Increases Bet on Bellus Health

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it has completed its previously-announced underwritten public offering in Canada and the United States (the “Offering”) of 17,888,889 common shares at a price to the public of US$2.25 per common share, which inc

BELLUS Health Closes US$40 Million Public Offering of Common Shares in Canada and the United States, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

LAVAL, Quebec--(BUSINESS WIRE)--In connection with its previously announced public offering of common shares in Canada and the United States (the “Offering”), BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU) today announced that it has entered into an underwriting agreement with a syndicate of underwriters comprising Jefferies and Evercore ISI as joint book-running managers, and LifeSci Capital as co-manager (collectively, the “Underwriters”), relating to the public o

BELLUS Health Announces Pricing of US$35 Million Public Offering in Canada and the United States

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (NASDAQ:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced the planned trial design for SOOTHE, the Company’s Phase 2b dose confirmation trial evaluating the efficacy and safety of BLU-5937 in refractory chronic cough (RCC).

BELLUS Health Announces Design for its Phase 2b Trial with BLU-5937 in Refractory Chronic Cough

Bellus (BLU) delivered earnings and revenue surprises of 26.32% and -42.86%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Bellus Health (BLU) Reports Q2 Loss, Lags Revenue Estimates

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the second quarter ended June 30, 2020.

BELLUS Health Reports Second Quarter 2020 Financial Results and Business Highlights

Bellus (BLU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bellus Health (BLU) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Genius Brands

Optical Cable

Zedge

The economy has been tumultuous, but technical analysis helps us see through the static and zero in on the best penny stock opportunities.

Penny Stocks to Buy Using Technical Analysis for August 2020

San Francisco, California--(Newsfile Corp. - July 13, 2020) -  Hagens Berman urges investors in BELLUS Health Inc. (NASDAQ: BLU) to submit their losses now.  The firm is investigating possible violations of federal securities laws, and certain investors may have valuable claims.  Hagens Berman also encourages persons who may be able to assist the Firm's investigation to contact its attorneys.Relevant Holding Period: Before July 6, 2020Visit: www.hbsslaw.com/investor-fraud/BLUContact an Attorney Now: BLU@hbsslaw.com844-916-0895BELLUS Health (BLU)...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds BELLUS Health (BLU) Investors of Firm's Investigation of Possible Securities Fraud, Encourages Investors and Persons Who May be Able to Assist Investigation to Contact the Firm

NEW YORK, July 10, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BELLUS Health Inc. ("BELLUS" or "the Company") (NASDAQ: BLU). Investors who purchased BELLUS securities are encouraged to obtain...

BLU Investor Update: Bronstein, Gewirtz & Grossman, LLC Notifies BELLUS Health Inc. Investors of Investigation and Encourages Investors to Contact the Firm

San Francisco, California--(Newsfile Corp. - July 8, 2020) -  Hagens Berman urges investors in BELLUS Health Inc. (NASDAQ: BLU) to submit their losses now.  The firm is investigating possible violations of federal securities laws, and certain investors may have valuable claims.  Hagens Berman also encourages persons who may be able to assist the Firm's investigation to contact its attorneys.Relevant Holding Period: Before July 6, 2020Visit: www.hbsslaw.com/investor-fraud/BLUContact an Attorney Now: BLU@hbsslaw.com844-916-0895BELLUS Health (BLU)...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Notifies BELLUS Health (BLU) Investors of Proprietary Investigation of Possible Securities Fraud, Encourages Investors and Persons Who May be Able to Assist Investigation to Contact the Firm

The company's lead drug has failed a phase 2 trial.

Why Bellus Health Stock Tanked 69.2% Today

Canadian biopharma BELLUS Health Inc (NASDAQ: BLU) was losing about three-fourths of its value in Monday's trading session.

Bellus Health Tumbles On Failed Midstage Study Of Lead Drug

As of late, it has definitely been a great time to be an investor in BELLUS Health.

News for Bellus Health Inc Stock (BLU)